)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Disruptive Pharma
Disruptive Pharma (DPHA) investor relations material
Disruptive Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Q2 2026 marked a strategic shift with the completion of a reverse takeover, transitioning focus to the Formulite® platform for next-generation drug development and commercialization.
Financials for the period reflect the legacy Guard Therapeutics business, not the new Disruptive Pharma operations.
Formulite® is positioned as a patented, clinically validated technology aimed at improving solubility, stability, and bioavailability of oral drugs.
The business model is partner-driven, targeting collaborations, licensing, and milestone/royalty revenues.
Financial highlights
Net sales were 0 KSEK for both Q2 and H1 2026 (unchanged year-over-year).
Net result for Q2: -4,364 KSEK (improved from -32,221 KSEK year-over-year); H1: -10,716 KSEK (improved from -66,436 KSEK year-over-year).
EPS for Q2: -0.22 SEK (vs. -1.66); H1: -0.53 SEK (vs. -4.19).
Cash and equivalents at June 30: 34,105 KSEK (down from 100,481 KSEK year-over-year).
Equity at period end: 32,178 KSEK (vs. 80,395 KSEK prior year).
Outlook and guidance
The company expects its financial resources post-transaction to support operations and strategic investments for approximately 18 months, even without revenues.
Focus is on expanding Formulite® projects, scaling manufacturing, and establishing strategic partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Disruptive Pharma
- Q1 loss narrowed, cash reserves rose, and delisting looms pending strategic alternatives.DPHA
Q1 2026 - RMC-035 program ended after negative trial; strategic review and cost cuts underway.DPHAQ4 2025
- Negative POINTER study results prompt strategic review and development pause.DPHAQ3 2025
- Phase 2b POINTER showed no significant kidney benefit for RMC-035, prompting strategic review.DPHAStudy Result
- Phase 2b POINTER study recruitment completed early; positive safety review and SEK 120M raised.DPHAQ2 2025
- Phase 2b POINTER study underway; RMC-035 targets $1B+ global market in cardiac surgery.DPHAQ3 2024
- Regulatory progress and new funding position Guard Therapeutics for key clinical milestones.DPHAQ2 2024
- Q1 saw rapid clinical progress and SEK 120m in new funding, despite a widened loss.DPHAQ1 2025
- Net loss widened as R&D ramped up for POINTER; major capital raise planned for 2025 milestones.DPHAQ4 2024
Next Disruptive Pharma earnings date
Q3 202612 Nov, 2026
Disruptive Pharma
Next Disruptive Pharma earnings date
Q3 202612 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage